Search results
Stelara interactions: Other medications, alcohol, and more
Medical News Today· 1 day agoStelara (ustekinumab) is a brand-name injectable drug prescribed for certain autoimmune conditions....
Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition...
Rome Sentinel· 2 days agoAdalimumab-aaty is also available from Celltrion USA under the brand name YUFLYMA®, which launched in July 2023 and is available at a 5% discount to the current WAC list price of HUMIRA. Adalimumab-aaty ...
Kim Kardashian’s Met Gala Look Had 1 Detail So Extreme It Made People Uncomfortable
The Huffington Post· 4 days agoThe reality TV star wore a custom Maison Margiela Artisanal gown by John Galliano with a metal...
3 Tried and True Dividend Stocks to Buy for Your Portfolio
InvestorPlace· 4 days agoPicking income stocks can be challenging. It varies year to year, but holding solid income stocks...
Merit Financial Group LLC Cuts Stock Position in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 4 days agoMerit Financial Group LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 17.9% in the fourth quarter, according to the company in its most recent 13F filing with the ...
Amgen (NASDAQ:AMGN) Price Target Cut to $328.00
ETF DAILY NEWS· 7 days agoAmgen (NASDAQ:AMGN – Get Free Report) had its price target reduced by Royal Bank of Canada from $332.00 to $328.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently ...
Johnson & Johnson (NYSE:JNJ) Shares Purchased by Metis Global Partners LLC
ETF DAILY NEWS· 2 days agoMetis Global Partners LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 17.6% in the 4th quarter, according to its most recent disclosure with the Securities and ...
Johnson & Johnson (NYSE:JNJ) Shares Sold by Wealthcare Advisory Partners LLC
ETF DAILY NEWS· 1 day agoWealthcare Advisory Partners LLC reduced its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 3.4% in the 4th quarter, according to the company in its most recent filing with the Securities ...
Analysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $21.75
ETF DAILY NEWS· 3 days agoVentyx Biosciences, Inc. (NASDAQ:VTYX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat ...